These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 25136972)
1. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry. González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972 [TBL] [Abstract][Full Text] [Related]
2. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182 [TBL] [Abstract][Full Text] [Related]
3. Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Tsuruoka M; Hara J; Hirayama A; Sugimoto M; Soga T; Shankle WR; Tomita M Electrophoresis; 2013 Oct; 34(19):2865-72. PubMed ID: 23857558 [TBL] [Abstract][Full Text] [Related]
4. Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. González-Domínguez R; García-Barrera T; Gómez-Ariza JL Anal Bioanal Chem; 2014 Nov; 406(28):7137-48. PubMed ID: 25230597 [TBL] [Abstract][Full Text] [Related]
5. Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. González-Domínguez R; García-Barrera T; Gómez-Ariza JL J Pharm Biomed Anal; 2014 Sep; 98():321-6. PubMed ID: 24992214 [TBL] [Abstract][Full Text] [Related]
6. Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease. González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL J Pharm Biomed Anal; 2015 Mar; 107():378-85. PubMed ID: 25656489 [TBL] [Abstract][Full Text] [Related]
7. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease. González-Domínguez R; García-Barrera T; Gómez-Ariza JL J Pharm Biomed Anal; 2015 Mar; 107():75-81. PubMed ID: 25575172 [TBL] [Abstract][Full Text] [Related]
8. Metabolic profiling for the identification of Huntington biomarkers by on-line solid-phase extraction capillary electrophoresis mass spectrometry combined with advanced data analysis tools. Pont L; Benavente F; Jaumot J; Tauler R; Alberch J; Ginés S; Barbosa J; Sanz-Nebot V Electrophoresis; 2016 Mar; 37(5-6):795-808. PubMed ID: 26685060 [TBL] [Abstract][Full Text] [Related]
9. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS. Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189 [TBL] [Abstract][Full Text] [Related]
13. Capillary electrophoresis mass spectrometry as a tool for untargeted metabolomics. García A; Godzien J; López-Gonzálvez Á; Barbas C Bioanalysis; 2017 Jan; 9(1):99-130. PubMed ID: 27921456 [TBL] [Abstract][Full Text] [Related]
14. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. Peña-Bautista C; Roca M; Hervás D; Cuevas A; López-Cuevas R; Vento M; Baquero M; García-Blanco A; Cháfer-Pericás C J Proteomics; 2019 May; 200():144-152. PubMed ID: 30978462 [TBL] [Abstract][Full Text] [Related]
15. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. Graham SF; Chevallier OP; Elliott CT; Hölscher C; Johnston J; McGuinness B; Kehoe PG; Passmore AP; Green BD PLoS One; 2015; 10(3):e0119452. PubMed ID: 25803028 [TBL] [Abstract][Full Text] [Related]
16. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586 [TBL] [Abstract][Full Text] [Related]
17. Blood-based diagnosis of Alzheimer's disease using fingerprinting metabolomics based on hydrophilic interaction liquid chromatography with mass spectrometry and multivariate statistical analysis. Inoue K; Tsuchiya H; Takayama T; Akatsu H; Hashizume Y; Yamamoto T; Matsukawa N; Toyo'oka T J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 974():24-34. PubMed ID: 25463194 [TBL] [Abstract][Full Text] [Related]
18. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease. Peng J; Guo K; Xia J; Zhou J; Yang J; Westaway D; Wishart DS; Li L J Proteome Res; 2014 Oct; 13(10):4457-69. PubMed ID: 25164377 [TBL] [Abstract][Full Text] [Related]
19. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach. Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504 [TBL] [Abstract][Full Text] [Related]
20. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]